RYVU (RVU)
Last updated: Source: ESEF / ESPI / GPW
Price Chart
Key Statistics
52W High
32.50 PLN
52W Low
13.64 PLN
About RYVU
Ryvu Therapeutics is a biotechnology company developing innovative small molecule drugs, primarily in oncology. The most advanced project is a CDK8/19 inhibitor in Phase II clinical trials.
This description was generated with the help of AI and may contain inaccuracies. Please verify important information from official sources.
Communities
News
No news for RVU.
Company Details
Data sourced from GPW and OpenFIGI. Updated periodically — verify with official sources.
Similar companies — equity
Explore the market
This information is provided for informational purposes only and does not constitute investment advice or a recommendation. Listings describe companies by the stated criteria and are not an inducement to buy or sell any financial instrument. Verify figures against official sources before making any investment decision.